1199809-30-7

Basic information

• Product Name: (2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine
• Synonyms: (2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine
• CAS NO: 1199809-30-7
• Molecular Formula: C13H18FN5O4
• Molecular Weight: 327.315
• Mol File: 1199809-30-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine(CAS DataBase Reference)
• NIST Chemistry Reference: (2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine(1199809-30-7)
• EPA Substance Registry System: (2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine(1199809-30-7)

Safety Data

• Hazardous Substances Data: 1199809-30-7(Hazardous Substances Data)

Usage

Description

(2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine is a modified nucleoside guanosine compound characterized by a deoxyribose sugar molecule with a 6-O-ethyl substituent and 2'-fluoro and 2'-methyl modifications on the guanosine base. These modifications enhance the compound's stability and resistance to nuclease degradation, making it a promising candidate for research and drug development.

Uses

Used in Antiviral Applications:
(2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine is used as a potential antiviral agent for inhibiting viral replication by interfering with viral RNA synthesis. Its increased stability and resistance to degradation contribute to its effectiveness in combating viral infections.
Used in Nucleoside Analog Therapy:
In the pharmaceutical industry, (2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine is used as a nucleoside analog for the treatment of viral infections. Its unique structure allows it to be incorporated into viral RNA, thereby inhibiting the replication process and providing therapeutic benefits.
Used in Cancer Treatment Research:
(2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine is also used in research for the development of cancer treatment strategies. Its ability to interfere with nucleic acid synthesis may offer potential applications in targeting rapidly dividing cancer cells, contributing to the advancement of oncology therapies.

Upstream product

• 64-17-5 ethanol 
• 1294481-82-5 (2R,3R,4R,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-2-(((4-chlorobenzoyl)oxy)methyl)-4-fluoro-4-methyltetrahydrofuran-3-yl 4-chlorobenzoate 
• 1199809-22-7 ((2R,3R,4R,5R)-3-(benzoyloxy)-4-fluoro-5-hydroxy-4-methyltetrahydrofuran-2-yl)methyl benzoate 
• 1199809-26-1 (2R,3R,4R,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-2-((benzoyloxy)methyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate 
• 141-52-6 sodium ethanolate 
• 1199809-24-9 (((2R,3R,4R,5R)-3-(benzoyloxy)-5-bromo-4-fluoro-4-methyltetrahydrofuran-2-yl)methyl benzoate) 
• 874638-80-9 ((2R,3R,4R)-3-benzoyloxy-4-fluoro-4-methyl-5-oxo-tetrahydrofuran-2-yl)methyl benzoate 
• 10310-21-1 2-Amino-6-chloropurin 
• 1294481-81-4 (2R,3R,4R,5R)-5-bromo-2-(((4-chlorobenzoyl)oxy)methyl)-4-fluoro-4-methyltetrahydrofuran-3-yl 4-chlorobenzoate 
• 1294481-80-3 ((2R,3R,4R,5R)-3-((4-chlorobenzoyl)oxy)-4-fluoro-5-hydroxy-4-methyltetrahydrofuran-2-yl)methyl 4-chlorobenzoate 
• 1294481-79-0 ((2R,3R,4R) 3-(4-chlorobenzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydrofuran-2-yl)methyl-4-chlorobenzoate 

Downstream Products

• 1199809-32-9 PSI-938 
• 1199809-77-2 6-ethoxy-9-((2S,4aR,6R,7R,7aR)-7-fluoro-2-isopropoxy-7-methyl-2-oxo-tetrahydro-2λ(5)-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl)-9H-purin-2-ylamine 
• 1604813-61-7 C₂₆H₂₇FN₅O₇P 
• 1604813-47-9 C₄₁H₅₁FN₁₂O₁₃P₂ 
• 1604813-50-4 C₃₉H₄₉FN₁₂O₁₃P₂ 
• 1261253-86-4 C₂₄H₃₂FN₆O₈P 
• 1261254-05-0 C₂₃H₃₀FN₆O₈P 
• 1261254-07-2 C₂₅H₃₄FN₆O₈P 

Relevant articles and documents

The synthesis of hydroxyaminopurine nucleosied (by machine translation)

A compound or salt thereof having the following structure useful for the treatment of hepatitis C virus (HCV): wherein R 7 is C 1-6 alkyl or C 3-6 cycloalkyl and R 8 is -O(C 1-6 alkyl) or -O(C 3-6 cycloalkyl).

Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or i

2′-Deoxy-2′-α-fluoro-2′-β-C-methyl 3′,5′-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: Discovery of PSI-352938

A series of novel 2′-deoxy-2′-α-fluoro-2′-β-C- methyl 3′,5′-cyclic phosphate nucleotide prodrug analogs were synthesized and evaluated for their in vitro anti-HCV activity and safety. These prodrugs demonstrated a 10-100-fold greater potency than the parent nucleoside in a cell-based replicon assay due to higher cellular triphosphate levels. Our structure-activity relationship (SAR) studies provided compounds that gave high levels of active triphosphate in rat liver when administered orally to rats. These studies ultimately led to the selection of the clinical development candidate 24a (PSI-352938).